Sharechat Logo

Pacific Edge Limited (NZX: PEB) United Healthcare Issues Positive Coverage Cxbladder

Friday 9th April 2021

Text too small?

Cancer diagnostics company, Pacific Edge Limited is pleased to advise that its Cxbladder bladder cancer diagnostic tests are now covered by United Healthcare, the largest healthcare group in the US.

Effective from 1 April 2021, Cxbladder is now being covered as a ‘medically necessary bladder tumor marker test’, under United Healthcare’s Molecular Pathology/Molecular Diagnostics/Genetic Testing (Medicare Advantage) - Medical Policy.

United Healthcare has over 50 million members with more than 5.7 million Medicare Advantage members. In 2019, UnitedHealth Group had a 14.1 percent share of the U.S. health insurance market, with direct premiums written amounting to approximately US$107 billion . The organisation partners with 6,500 hospitals and care facilities nationwide, and more than 1.3 million physicians and other providers.

Including the positive coverage decision issued by the Centres for Medicare and Medicaid Services (CMS) in 2020, more than 110 million Americans now have coverage of Cxbladder non-invasive, highly accurate tests for the detection and management of urothelial and bladder cancer.

Pacific Edge CEO David Darling states: “Gaining coverage with the US’ largest insurer is a significant achievement for Pacific Edge and will be of benefit to millions of Americans seeking better clinical solutions and health outcomes for bladder cancer diagnosis.

“This positive coverage decision reflects the validation that comes from independent published clinical evidence, inclusion in guidelines and coverage with other providers such as the CMS. It adds further validation of Cxbladder and a point of inflexion for other healthcare insurers.”

Please see the link below for details:

United Healthcare Issues Positive Coverage Decision for Cxbladder

Source: Pacific Edge Limited

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

BIF - Acquires shares in Hot Lime Labs
RUA - Cann Group granted TGA GMP for Mildura facility
AFI - Invitation to Results Webcast
PFI Share Buyback Programme to Pause
Greenfern Industries Limited ("GFI") - Late Annual Report
FSF - Monthly Allotment/ Redemption Notice
1st July 2022 Morning Report
General Capital Releases 2022 Annual Report
Fonterra, NZX, EEX confirm GDT strategic partnership
BIF - Annual Report 2022